Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
Bruce Anthony Campbell CreeJeffrey A CohenAnthony T RederDavorka TomicDiego SilvaDaniela Piani MeierAnnik K LaflammeShannon RitterDavid LeppertLudwig KapposPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
CDI and SDI are outcomes of interest for clinical trials and for long-term follow-up of participants with RMS. Monitoring CDI and SDI in addition to disability worsening may facilitate understanding of the therapeutic benefit of RMS treatments.